Canntab Therapeutics

What Canntab Therapeutics does

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company headquartered in Markham, Ontario that develops, manufactures, and distributes pharmaceutical-grade hard pill (tablet and caplet) cannabinoid formulations for medical cannabis patients. The company operates a manufacturing facility at 223 Riviera Drive in Markham under a suite of Health Canada licenses, including Cannabis Standard Processing & Sales for Medical Purposes, Medical Sales, Export, Industrial Hemp, and Cannabis Research authorizations. Its product portfolio comprises THC-only instant-release tablets in 2.5mg, 5mg, 10mg, and 25mg strengths; CBD-only tablets in 12.5mg and 25mg strengths; and combination THC/CBD caplets in fixed ratios, marketed under the InstaCann brand through provincial retailers and as medical products via the company's own e-commerce platform.

The technological core of the business is a patented multi-layer tablet architecture combining Instant Release (IR) and Extended Release (XR) layers, supported by proprietary nano-emulsification technology intended to improve oral bioavailability of cannabinoids by addressing hepatic first-pass metabolism. Canntab holds three granted patents (US Patent No. 10,772,837, Canadian Patent CA 3050150, Australian Patent AU 2018210690) expiring in 2038, with eleven additional patents pending internationally across oral dissolvable tablets, opioid-addiction formulations, and nano-emulsification processes.

Revenue is generated through three channels: direct product sales via the canntab.ca DTC e-commerce platform to patients with valid medical documents; wholesale distribution through licensed producers and provincial cannabis retailers such as OCS, NSLC, and Saskatchewan, plus international distribution via Cann Global Limited to Australia; and affiliate/referral revenue from pharmacy networks (OnPharm-United's 600+ Ontario pharmacies), pain and wellness clinics (Pathway Health's 9 clinics across 4 provinces and Levitee Clinics servicing 35,000 annual visits), and individual healthcare professionals. Pricing is per-unit with Veterans Affairs coverage at C$8.50/gram (up to 3 grams/day), partial private insurer coverage (e.g., Sun Life for cancer pain, MS, RA, HIV, palliative care), and out-of-pocket or Health Care Spending Account payment for the balance of demand.

Name

Canntab Therapeutics

Legal name

Canntab Therapeutics Limited

Website

https://canntab.ca

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company that develops and manufactures patented hard pill (tablet and caplet) cannabinoid formulations — Instant Release and Extended Release THC, CBD, and combination products — for medical cannabis patients in Canada and Australia, distributing via e-commerce, provincial retailers, and pharmacy/clinic affiliate networks.

Ownership category

akta.pro rank

Headquarters

HQ city

Markham

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Direct Product Sales: Direct-to-consumer sales of medical cannabis tablets and caplets through e-commerce platform to patients with valid medical prescriptions. Products sold include THC-only, CBD-only, and combined THC/CBD formulations in multiple dosage strengths.
2. Wholesale Distribution: Wholesale sales to licensed producers, distributors, and provincial retailers including MediPharm Labs agreement (~$1.3M contract), provincial cannabis stores (OCS, NSLC), and international partners.
3. Affiliate/Referral Revenue: Revenue through affiliate partnerships where pharmacies, clinics, and healthcare professionals recommend or prescribe products and receive compensation for patient referrals.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels5 records

Core offering

Canntab Therapeutics manufactures and distributes pharmaceutical-grade hard tablet and caplet cannabinoid formulations for medical cannabis patients. Its portfolio includes THC-only tablets (2.5mg, 5mg, 10mg, 25mg), CBD-only tablets (12.5mg, 25mg), and fixed-ratio THC/CBD combination caplets, built on patented Instant Release and Extended Release tablet technologies with proprietary nano-emulsification for enhanced bioavailability. Products are sold through direct-to-consumer e-commerce, provincial cannabis retailers, pharmacy affiliate networks, clinic partnerships, and international distributors in Canada and Australia.

Product overview

Canntab Therapeutics is a Canadian phytopharmaceutical company that manufactures and distributes hard pill (solid oral dosage) cannabinoid formulations. The product portfolio includes THC-only tablets (2.5mg, 5mg, 10mg, 25mg), CBD-only tablets (12.5mg, 25mg), and THC/CBD combination caplets in various strengths. The company offers two proprietary formulation technologies: Instant Release (IR) formulations using nano-emulsification for rapid onset, and Extended Release (XR) formulations for once-daily sustained delivery. Products are marketed under the InstaCann brand for recreational/medical provincial channels and as medical products through the company's e-commerce platform.

Differentiator

Problem solved

Functional benefit

Products and services

• THC Tablets (Instant Release) Hard oral tablet formulations delivering tetrahydrocannabinol (THC) in precise dosages for medical cannabis patients, available in 2.5mg, 5mg, 10mg, and 25mg strengths using Canntab's patented Instant Release nano-emulsification technology.

Quantifiable outcome

• Enhanced oral bioavailability through inhibition of hepatic first-pass metabolism
• +1 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Hamish Sutherland (Strategic Advisor)minorStrategic or Co-development Partner · 13 April 2022Engaged as strategic business consultant to develop additional sales and distribution channels and assist with strategic partnerships. Former founding COO of Bedrocan Canada (acquired by Canopy Growth). Initial 4-month engagement at $5,000/month plus 40,000 shares and 200,000 stock options at $0.50.
• OnPharm-UnitedcoreChannel Partner/ Reseller/ Distributor · 23 March 2022Affiliate agreement with network of over 600 independent pharmacies in Ontario. Member pharmacies receive educational materials on medical cannabis and access to Canntab's product catalog. Pharmacists can refer patients to the Canntab.ca website for prescription fulfillment and receive compensation.
• Levitee Clinics Inc.coreStrategic or Co-development Partner · 16 December 2021Strategic partnership to provide alternatives to opiates through integrative wellness clinics. Levitee operates three pharmacies in Alberta specializing in substance use disorders, mental health, and chronic pain. Serviced over 35,000 patient visits in prior 12 months. Canntab's full suite of THC and CBD tablets made available to patients.
• Pathway Health CorporationcoreStrategic or Co-development Partner · 2 December 2021Service agreement with one of Canada's largest out-of-hospital pain management providers. Pathway operates 9 community-based clinics across 4 provinces with medical cannabis-focused virtual clinics. Both companies will collaborate on educational resources for patients.
• Cann Global LimitedcoreChannel Partner/ Reseller/ Distributor · 9 March 2021Australian distribution partner for hard pill cannabinoid formulations. Initial purchase order of $406,200 for 6 SKUs including THC, CBD, and combination products. Products distributed to medical distributors, doctors, pharmacies, and hospitals in Australia. Participation in Australia's CMOS observational study with 20,000 patients.
• Applied Cannabis Research (ACR)minorStrategic or Co-development Partner · 26 October 2020Australian contract research organization leading the Cannabinoid Medicine Observational Study (CMOS). Canntab participating through Cann Global to collect data from 20,000 patients nationwide over 5 years assessing safety and efficacy for conditions including fibromyalgia, chronic pain, PTSD, epilepsy.
• CMAX Technologies Inc.minorOthers · 26 October 2020Related party from which Canntab acquired cannabis-processing equipment and leasehold improvements at its Markham facility for $1,018,000 through issuance of 1,996,078 common shares. Shareholders include company founders and executives.
• Pharmagenerics Solutions Inc.minorOthers · 19 October 2020Vendor from which Canntab acquired cannabis-processing equipment for $300,000 through issuance of 588,235 common shares. Sole officer, director, and shareholder is Joshi Laxminarayan, Chief Scientific Officer of Canntab.
• MediPharm Labs Corp.coreChannel Partner/ Reseller/ Distributor · 2 June 2020Wholesale tablet purchase agreement valued at approximately $1.3 million for distribution of THC, CBD, and combination tablets across Canadian provincial dispensaries. First purchase agreement and order received June 2020. Canntab completed 80% of contract by March 2021.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MediPharm Labs Corp. Canadian cannabis extractor and manufacturer that is also a wholesale distribution partner of Canntab under a ~C$1.3M tablet purchase agreement. Operates in the same pharmaceutical-grade cannabis manufacturing category with similar Health Canada licensing and B2B distribution focus.
• Levitee Clinics Inc. Canadian wellness and addiction-medicine clinic operator and active Canntab distribution partner. Comparable as a clinical channel in the medical cannabis and pain-management ecosystem, with overlapping patient bases and partner relationships.
• Cann Global Limited: Australian medical cannabis distributor and partner that placed Canntab's initial C$406K purchase order and connects the company to doctors, pharmacies, hospitals, and the 20,000-patient CMOS observational study in Australia.

Broad incumbents

• Tilray Brands: Large Canadian-licensed cannabis producer with pharmaceutical and wellness product lines. Comparable as a competitor in the medical cannabis category, with substantially broader product portfolio, international footprint, and physician-channel reach than Canntab.
• Canopy Growth Corporation: Major Canadian cannabis producer formed via the Tweed/Bedrocan combination — directly relevant because Canntab's strategic advisor Hamish Sutherland co-founded Bedrocan Canada. Competes in the medical cannabis channel and validates the broader market Canntab is targeting.
• OrganiGram Holdings: Canadian licensed cannabis producer with a portfolio spanning dried flower, oil, and edible formats for both medical and adult-use channels. Competes with Canntab's tablet format for share of medical-cannabis prescriptions and provincial listings.
• Aurora Cannabis: Large Canadian cannabis producer with established medical cannabis sales, EU GMP-certified cultivation, and a wide product range. Comparable as a competing supplier to pharmacy networks and provincial retailers in Canada.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Epidiolex, the first FDA-approved plant-derived cannabinoid pharmaceutical. Sets the regulatory template Canntab aspires to as it pursues pharmaceutical-grade cannabinoid delivery, and represents the gold-standard pharmaceutical-cannabis benchmark.

Emerging players

• Zynerba Pharmaceuticals: Clinical-stage pharmaceutical company developing transdermal cannabinoid therapies for rare neurological conditions. Comparable as a small-cap pharma-cannabis player pursuing differentiated delivery formats and prescription-led adoption.
• Lexaria Bioscience: Cannabinoid delivery technology company with proprietary bioavailability-enhancing formulation IP. Compares to Canntab on the technology-and-IP axis, although Lexaria focuses on oral and topical formats rather than compressed tablets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Canntab_
• Facebookfacebook.com/CanntabTherapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canntab Therapeutics